propane (18:1 DOTAP), 1,2-dioleoyl-*sn*-glycero-3-phospho-(1'-*rac*-glycerol) (DOPG), 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-*sn*-glycero-3-phosphoethanolamine (DPPE), 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (18:1 PEG-2000 PE), 1,2-dipalmitoyl-*sn*-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (16:0 PEG-2000 PE), 1-Oleoyl-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]lauroyl]-*sn*-Glycero-3-Phosphocholine (18:1-12:0 NBD PC), 1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]lauroyl}-*sn*-glycero-3-phosphocholine (16:0-12:0 NBD PC), cholesterol and mixtures/combinations thereof,
and wherein (1) the lipid bilayer is loaded with SP94 and an fusogenic peptide, and (2) the protocell selectively binds to a hepatocellular carcinoma cell.

37. A pharmaceutical composition comprising the protocell composition according to any one of claims 1-36 in an amount effective to produce a therapeutic effect in a subject in combination with a pharmaceutically acceptable carrier, additive or excipient.

38. The pharmaceutical composition according to claim 37 further comprising a drug ~~which is not disposed as cargo within the protocell~~in addition to the plurality of protocells.

39. The pharmaceutical composition according to claims 37 or 38 in parenteral dosage form.

40. The pharmaceutical composition according to claim 39 wherein said dosage form is intradermal, intramuscular, intraosseous, intraperitoneal, intravenous, subcutaneous or intrathecal.

41. The pharmaceutical composition according to any one of claims 37-40 for use in the treatment of a subject who suffers from a cancer.

42. The pharmaceutical composition according to claim 41, wherein said cancer is metastatic.

43. The protocell composition according to any one of claims 1-28 and 30-36, wherein the nanoporous silica or metal oxide is a nanoporous silica core.